A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors

Current treatments for advanced solid tumors tend to be only palliative. Although radiotherapy is administered with a curative intent, radioresistance and dose-limiting toxicities pose limitations to treatment. Abexinostat, an oral pan-histone deacetylase inhibitor, demonstrated enhanced sensitivity...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Deutsch, Eric, Moyal, Elizabeth Cohen-Jonathan, Gregorc, Vanesa, Zucali, Paolo Andrea, Menard, Jean, Soria, Jean-Charles, Kloos, Ioana, Hsu, Jeff, Luan, Ying, Liu, Emily, Vezan, Remus, Graef, Thorsten, Rivera, Sofia
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593555/
https://ncbi.nlm.nih.gov/pubmed/28915584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14147
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars